<DOC>
	<DOCNO>NCT01718301</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy Response Guided Therapy boceprevir 800 mg dose three time day ( TID ) orally ( PO ) combination Peginterferon ( either alpha 2b alpha 2a ) Ribavirin HIV/HCV genotype 1 infected patient fail previous HCV therapy .</brief_summary>
	<brief_title>HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously Peginterferon /Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For inclusion study , subject must qualify regimen define peginterferon alfa2a plus ribavirin peginterferon alfa2b plus ribavirin minimum 12 week . If subject receive one regimen , recent regimen consider qualify regimen . Subject must previously document chronic hepatitis C ( CHC ) genotype 1 infection . Subjects mixed genotype eligible . The HCVRNA result screen visit must confirm genotype 1 infection ≥10,000 IU/mL . Subject must liver biopsy histology consistent CHC etiology and/or Fibroscan assessment . In case : 1 . No cirrhosis . Biopsies and/or Fibroscan must within 18 month screen visit . 2 . Cirrhosis . No specific length time would request . All patient cirrhosis must ultrasound 6 month within screen visit . Patients must stable antiretroviral therapy include CD4 cell count 100 per mm3 HIV plasmatic viral load undetectable ( &lt; 50 copies/mL ) 6 month . Antiretroviral therapy must Raltegravirbased ( al least last 3 month ) . Subject must ≥18 year age . HIV treatment contain efavirenz ( EFV ) , nevirapine ( NVP ) , etravirine ( ETV ) , didanosine ( ddI ) , stavudine ( d4T ) , zidovudine ( AZT ) , HIV protease inhibitor . Subject must weight 40 kg 125 kg . Subject subject 's partner ( ) must agree use acceptable method contraception least 2 week prior Day 1 continue least 6 month last dose study drug . Subjects must willing give write informed consent investigator opinion able follow protocol visit design . Subjects know coinfected hepatitis B virus ( HBsAg positive ) . Patients chronically infected HCV genotype 1 CD4 cell count &lt; 100 cel/mm3 . Plasma HIV RNA 50 copies/mL Platelet count le 80.000 /mm3 Subjects require discontinuation previous interferon ribavirin regimen severe adverse event consider investigator possibly probably related ribavirin and/or interferon . Treatment ribavirin within 90 day interferonalpha within 1 month Screening . Treatment hepatitis C investigational medication . Prior treatment herbal remedy know hepatotoxicity exclusionary . Participation clinical trial within 30 day randomization intention participate another clinical trial participation study . History hemoglobinopathy ( e.g. , thalassemia ) cause tendency hemolysis . Evidence decompensate liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy . Diabetic and/or hypertensive subject clinically significant ocular examination finding . Unstable untreated preexist psychiatric condition . Any known preexisting medical condition could interfere subject 's participation completion study . Any current evidence substance abuse alcohol drug . Subjects receive opioid agonist substitution therapy enrol opiate substitution maintenance program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>HIV</keyword>
	<keyword>Coinfection</keyword>
</DOC>